menu
    • menu
    [{"orgOrder":0,"company":"Lotte Biologics","sponsor":"PINOTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Lotte Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lotte Biologics \/ Lotte Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Lotte Biologics \/ Lotte Biologics"},{"orgOrder":0,"company":"Lotte Biologics","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2026","type":"Agreement","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lotte Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lotte Biologics \/ Lotte Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Lotte Biologics \/ Lotte Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Lotte Biologics

    Menu

    Lotte Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lotte Biologics

                            South Korea arrow
                            VMX
                            Not Confirmed

                            Lotte Biologics

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab Sarotalocan Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Rakuten Medical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Rakuten Medical, LOTTE Biologics Sign Agreement for Global Oncology Program

                            Details : As part of the agreement, Cetuximab Sarotalocan Sodium, an Antibody-drug Conjugate targeting Epidermal growth factor receptor erbB1, aims to address recurrent head and neck cancer.

                            Product Name : ASP-1929

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 14, 2026

                            Lead Product(s) : Cetuximab Sarotalocan Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Rakuten Medical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lotte Biologics

                            South Korea arrow
                            VMX
                            Not Confirmed

                            Lotte Biologics

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : PINOTBIO

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LOTTE BIOLOGICS Announces Investment in PINOT BIO, ADC Platform Development Pioneer

                            Details : The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeti...

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 21, 2023

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : PINOTBIO

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.